BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture studies identified an inhibitor of Q209L-mutant Gα-q that could help treat uveal melanoma harboring the mutation. In HEK cell-based signaling and activity assays, a previously reported cyclic depsipeptide-based inhibitor of Gα-q...
BioCentury | Mar 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: February 2018

New Therapeutic Targets and Biomarkers: February 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during February 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Feb 14, 2018
Distillery Therapeutics

Neurology

INDICATION: Addiction Mouse studies suggest inhibiting RGS20 could help treat morphine addiction. In periaqueductal gray samples from morphine-treated mice, levels of RGS20 protein were higher than in samples from vehicle-treated mice. In mice treated with...
BioCentury | Jan 27, 2017
Company News

Regeneus, Asahi Glass deal

Regeneus Ltd. (ASX:RGS), Pymble, Australia Asahi Glass Co. Ltd. (Tokyo:5201), Tokyo, Japan Business: Autoimmune, Gene/Cell therapy Regeneus and Asahi Glass formed a 50/50 JV to develop and commercialize osteoarthritis candidate Progenza in Japan. Regeneus received...
BioCentury | Nov 2, 2016
Distillery Techniques

Biomarkers

...high mRNA expression of genes not previously reported to be expressed in the pancreas, including regulator of G-protein signaling 4 (RGS4)...
...doi:10.1016/j.cmet.2016.08.020 CONTACT: Rickard Sandberg, Karolinska Institute, Stockholm, Sweden email: rickard.sandberg@ki.se Esme Gaisford Muscarinic acetylcholine receptor M3 (CHRM3) (HM3) Regulator of G-protein signaling 4 (RGS4)...
BioCentury | May 23, 2016
Clinical News

Progenza: Completed Phase I enrollment

Regeneus completed enrollment of 20 patients with Kellgren-Lawrence (KL) grade 2-3 OA of knee in the double-blind, placebo-controlled, dose-escalation, Australian Phase I STEP trial evaluating single doses of intra-articular Progenza. Regeneus Ltd. (ASX:RGS), Pymble, Australia...
BioCentury | Nov 16, 2015
Clinical News

RGSH4K: Phase I started

Regeneus began the open-label, dose-escalation, Australian Phase I ACTIVATE trial to evaluate intradermal RGSH4K using 100, 250 or 500 ug streptavidin on weeks 1, 4 and 7 in up to 21 patients. Regeneus Ltd. (ASX:RGS),...
BioCentury | May 11, 2015
Clinical News

Progenza: Phase I start

This quarter, Regeneus will begin the double-blind, placebo-controlled, dose-escalation, Australian Phase I STEP trial to evaluate single doses of intra-articular Progenza in 20 patients with Kellgren-Lawrence (KL) grade 2-3 OA of the knee. Regeneus Ltd....
BioCentury | Sep 29, 2014
Financial News

Regeneus completes private placement

Regeneus Ltd. (ASX:RGS), Pymble, Australia Business: Gene/Cell therapy Date completed: 2014-09-09 Type: Private placement Raised: A$3.4 million ($3 million) Shares: 13 million Price: A$0.26 Shares after offering: 208.1 million Investor: Existing investors Note: The financing...
BioCentury | Oct 24, 2013
Strategy

Synaptic synopsis

The early promise that neurotransmitter research would unlock the door for neurological diseases has devolved into sagging interest from several pharmas following repeated failures in clinical trials. Now, genetic findings are pointing to new targets...
Items per page:
1 - 10 of 26